Ex­clu­sive: Two biotechs merge to form Cal­lu­na, with €75M in hand to fo­cus on im­munother­a­py an­ti­bod­ies

A merg­er be­tween Ox­i­tope Phar­ma and Arxx Ther­a­peu­tics sees the birth of clin­i­cal-stage im­munother­a­py com­pa­ny Cal­lu­na, with €75 mil­lion ($81.6 mil­lion) in its pock­ets from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER